About US
Contact us
-
SFDA issues Criteria for Writing Drug Periodic Safety Update ReportsIn order to standardize and offer guidance to the writing of drug Periodic Safety Update Reports (PSUR), improve drug manufacturers’ ability to analyze and evaluate drug safety issues, the State Food2012/9/17
-
Hisun-Pfizer workforce to more than double in sizeIn a very ambitious drive, Pfizer ($PFE) and its Chinese joint-venture partner Zhejiang Hisun Pharmaceutical intend to more than double the size of the Hisun-Pfizer workforce by the end of the year.2012/9/14
-
J&J picks Bayer AG exec to solve its consumer product messJohnson & Johnson ($JNJ) has turned to an outsider to take over its troubled consumer products division and its attendant manufacturing mess. The company today announced Sandra Peterson, who ha2012/9/14
-
Merck's Singulair sales free-fall 90% in 4 weeksWith all of the pressures in place to promote generics of popular branded drugs, the time it takes to go from blockbuster to just buster has become remarkably short.New data shows that sales of Merc2012/9/13
-
Roche loses patent fight in India as Novartis fights onEven as Novartis ($NVS) is fighting a long anticipated battle in India to protect the patent on its cancer drug Gleevec, another Swiss drugmaker must decide if it will appeal a ruling that it believ2012/9/13
-
SFDA Commissioner Yin Li attends the 5th Joint ChP-USP International Symposium and 2012 ChP Scientific Annual MeetingOn September 6, 2012, the 5th Joint ChP-USP International Symposium and 2012 ChP Scientific Annual Meeting was opened in Xi’an. Yin Li, Commissioner of the State Food and Drug Administration (2012/9/12
-
India opens up its drugmakers to foreign investmentEven as Big Pharma watches a critical patent fight in India to see how restrictive the country intends to be, there was an indication the country would again welcome outside investments in the domes2012/9/12
-
Faltering drug development poses risk to future revenuesWith so many drugs falling off the patent cliff, and taking drugmakers' revenues down with them, there has been a penchant to bet on riskier new drugs with bigger potential payoffs. But a new report f2012/9/11
-
FDA gives generic drugs 'super' statusWith generic drugmakers now slated to kick in a significant piece of the FDA's outside funding, the agency appears ready to give them the position they have earned. According to a letter from Janet W2012/9/11
-
Drug shortages ease but remain serious problemPatients who can't get the drugs they need because they're in short supply will not be impressed by the news, but the problem ofdrug shortageshas so far been less severe this year than last. Through2012/9/10